Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 5897298, 9 pages
https://doi.org/10.1155/2017/5897298
Review Article

Aging in HIV-Infected Subjects: A New Scenario and a New View

1Lluita contra la Sida Foundation, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
2Universitat de Vic-Universidad Central de Catalunya (UVIC-UCC), Vic, Spain
3Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK
4Department of Infectious Diseases, Hospital San Pedro-CIBIR, Logroño, Spain
5AIDS Research Institute-IRSICAIXA, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain
6Department of Medicine, University of Colorado, Aurora, CO, USA
7Neuropsychology Unit-Brain, Cognition and Behavior: Clinical Research, Consorci Sanitari de Terrassa, Barcelona, Spain
8Department of Medical and Surgical Sciences for Children & Adults, University of Modena and Reggio Emilia, Modena, Italy
9University College Dublin School of Medicine and Medical Science, Dublin, Ireland
10Geriatric Department, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Facultad de Medicina, Universidad Complutense, CIBERFES, Madrid, Spain

Correspondence should be addressed to Eugenia Negredo

Received 28 September 2017; Accepted 16 November 2017; Published 21 December 2017

Academic Editor: Lucia Lopalco

Copyright © 2017 Eugenia Negredo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Christensen, G. Doblhammer, R. Rau, and J. W. Vaupel, “Ageing populations: the challenges ahead,” The Lancet, vol. 374, no. 9696, pp. 1196–1208, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Smit, K. Brinkman, S. Geerlings et al., “Future challenges for clinical care of an ageing population infected with HIV: A modelling study,” The Lancet Infectious Diseases, vol. 15, no. 7, pp. 810–818, 2015. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Pathai, H. Bajillan, A. L. Landay, and K. P. High, “Is HIV a model of accelerated or accentuated aging?” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 69, no. 7, pp. 833–842, 2014. View at Publisher · View at Google Scholar · View at Scopus
  4. J. R. Blanco, I. Jarrín, M. Vallejo et al., “Definition of Advanced Age in HIV-Infection: Looking for an Age Cut-Off,” AIDS Research and Human Retroviruses, vol. 28, pp. 800–806, 2012. View at Publisher · View at Google Scholar
  5. F. Brañas, J. Berenguer, M. Sánchez-Conde et al., “The Eldest of Older Adults Living with HIV: Response and Adherence to Highly Active Antiretroviral Therapy,” American Journal of Medicine, vol. 121, no. 9, pp. 820–824, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. T. J. Levett, F. V. Cresswell, M. A. Malik, M. Fisher, and J. Wright, “Systematic Review of Prevalence and Predictors of Frailty in Individuals with Human Immunodeficiency Virus,” Journal of the American Geriatrics Society, vol. 64, no. 5, pp. 1006–1014, 2016. View at Publisher · View at Google Scholar · View at Scopus
  7. G. Guaraldi, S. Zona, T. D. Brothers et al., “Aging with HIV vs. HIV seroconversion at older age:A diverse population with distinct comorbidity profiles,” PLoS ONE, vol. 10, no. 4, Article ID e0118531, 2015. View at Publisher · View at Google Scholar · View at Scopus
  8. G. Guaraldi, G. Orlando, S. Zona et al., “Premature age-related comorbidities among HIV-infected persons compared with the general populationa,” Clinical Infectious Diseases, vol. 53, no. 11, pp. 1120–1126, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. J. Schouten, F. W. Wit, I. G. Stolte, and et al., “AGEhIV Cohort Study Group. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study,” Clinical Infectious Diseases, vol. 59, pp. 1787–1797, 2014. View at Google Scholar
  10. C. Franceschi and J. Campisi, “Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 69, supplement 1, pp. s4–s9, 2014. View at Publisher · View at Google Scholar
  11. S. G. Deeks, “HIV infection, inflammation, immunosenescence, and aging,” Annual Review of Medicine, vol. 62, pp. 141–155, 2011. View at Publisher · View at Google Scholar
  12. B. Grund, J. V. Baker, S. G. Deeks et al., “Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy,” PLoS ONE, vol. 11, no. 5, Article ID e0155100, 2016. View at Publisher · View at Google Scholar · View at Scopus
  13. World Health Organization., World report on ageing and health, 2015.
  14. J. L. Goulet, S. L. Fultz, D. Rimland et al., “Do patterns of comorbidity vary by HIV status, age, and HIV severity?” Clinical Infectious Diseases, vol. 45, no. 12, pp. 1593–1601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. N. Meyer, J. E. Gallant, P. Y. Hsue, and X. Song, “Comorbidities of Patients with Human Immunodeficiency Virus (HIV) in the USA - a Longitudinal Analysis of Prevalent HIV Patients Over 11 Years,” in Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC ’15), San Diego, CA, USA, September 2015.
  16. B. Alejos, V. Hernando, J. López-Aldeguer et al., “Overall and cause-specific mortality in HIV-positive subjects compared to the general population,” Journal of the International AIDS Society, vol. 17, p. 19711, 2014. View at Publisher · View at Google Scholar
  17. P. Morlat, C. Roussillon, S. Henard et al., “Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000,” AIDS, vol. 28, no. 8, pp. 1181–1191, 2014. View at Publisher · View at Google Scholar
  18. C. J. Miller, J. V. Baker, A. M. Bormann et al., “Adjudicated morbidity and mortality outcomes by age among individuals with HIV infection on suppressive antiretroviral therapy,” PLoS ONE, vol. 9, no. 4, Article ID e95061, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. R. B. Effros, C. V. Fletcher, K. Gebo et al., “Workshop on HIV infection and aging: what is known and future research directions,” Clinical Infectious Diseases, vol. 47, no. 4, pp. 542–553, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Petoumenos and S. W. Worm, “HIV infection, aging and cardiovascular disease: Epidemiology and prevention,” Sexual Health, vol. 8, no. 4, pp. 465–473, 2011. View at Publisher · View at Google Scholar · View at Scopus
  21. F. Boccara, S. Lang, C. Meuleman et al., “HIV and coronary heart disease: time for a better understanding,” Journal of the American College of Cardiology, vol. 61, no. 5, pp. 511–523, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. J. Falutz, “HIV infection, body composition changes and related metabolic complications: Contributing factors and evolving management strategies,” Current Opinion in Clinical Nutrition & Metabolic Care, vol. 14, no. 3, pp. 255–260, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Srinivasa, K. V. Fitch, J. Lo et al., “Plaque burden in HIV-infected patients is associated with serum intestinal microbiota-generated trimethylamine,” AIDS, vol. 29, no. 4, pp. 443–452, 2015. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Y. Hsue, K. Squires, A. F. Bolger et al., “Screening and assessment of coronary heart disease in HIV-infected patients,” Circulation, vol. 118, no. 2, pp. e41–e47, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Regan, J. Meigs, S. Grinspoon, V. Triant, and M. Mosepele, “Application of new ACC/AHA cholesterol guidelines to an HIV clinical care cohort,” in Proceedings of the Mosepele M. Application of new ACC/AHA cholesterol guidelines to an HIV clinical care cohort. Abstract 734. Conference on retroviruses and opportunistic infections, pp. 23–26, Seattle, Washington, USA, 2015.
  26. C. M. Wyatt, J. A. Winston, C. D. Malvestutto et al., “Chronic kidney disease in HIV infection: an urban epidemic,” AIDS, vol. 21, no. 15, pp. 2101–2103, 2007. View at Publisher · View at Google Scholar
  27. W. K. Adih, R. M. Selik, and Xiaohong Hu, “Trends in diseases reported on US death certificates that mentioned HIV infection, 1996-2006,” Journal of the International Association of Physicians in AIDS Care, vol. 10, no. 1, pp. 5–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. Consensus development conference., “Diagnosis, prophylaxis, and treatment of osteoporosis,” American Journal of Medicine, vol. 94, pp. 646–650, 1993. View at Google Scholar
  29. J. D. Lundgren, J. M. Gatell, H. Furrer, and J. Rockstroh, EACS Guidelines version 8.1 October 2016. Available at: http://www.eacsociety.org/files/guidelines_8.1-english.pdf.
  30. T. T. Brown, J. Hoy, M. Borderi et al., “Recommendations for evaluation and management of bone disease in HIV,” Clinical Infectious Diseases, vol. 60, no. 8, pp. 1242–1251, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Guiguet, F. Boue, J. Cadranel, J. M. Lang, E. Rosenthal, and D. Costagliola, “Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study,” The Lancet Oncology, vol. 10, no. 12, pp. 1152–1159, 2009. View at Publisher · View at Google Scholar
  32. A. E. Grulich, M. T. van Leeuwen, M. O. Falster, and C. M. Vajdic, “Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis,” The Lancet, vol. 370, no. 9581, pp. 59–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Cañizares, M. Cherner, and R. J. Ellis, “HIV and aging: effects on the central nervous system,” Seminars in Neurology, vol. 34, no. 1, pp. 27–34, 2014. View at Publisher · View at Google Scholar · View at Scopus
  34. S. L. Cody and D. E. Vance, “The neurobiology of HIV and its impact on cognitive reserve: A review of cognitive interventions for an aging population,” Neurobiology of Disease, vol. 92, pp. 144–156, 2016. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Muscari, C. Giannoni, L. Pierpaoli et al., “Chronic endurance exercise training prevents aging-related cognitive decline in healthy older adults: A randomized controlled trial,” International Journal of Geriatric Psychiatry, vol. 25, no. 10, pp. 1055–1064, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. L. P. Fried, C. M. Tangen, J. Walston et al., “Frailty in older adults: evidence for a phenotype,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 56, no. 3, pp. M146–M156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. D. A. Piggott, K. M. Erlandson, and K. E. Yarasheski, “Frailty in HIV: Epidemiology, Biology, Measurement, Interventions, and Research Needs,” Current HIV/AIDS Reports, vol. 13, no. 6, pp. 340–348, 2016. View at Publisher · View at Google Scholar · View at Scopus
  38. L. Desquilbet, L. P. Jacobson, L. P. Fried et al., “HIV-1 Infection Is Associated With an Earlier Occurrence of a Phenotype Related to Frailty,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 62, no. 11, pp. 1279–1286, 2007. View at Publisher · View at Google Scholar
  39. L. Desquilbet, L. P. Jacobson, L. P. Fried et al., “A frailty-related phenotype before HAART initiation as an independent risk factor for AIDS or death after HAART among HIV-infected men,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 66, no. 9, pp. 1030–1038, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. L. Desquilbet, J. B. Margolick, L. P. Fried et al., “Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men,” Journal of Acquired Immune Deficiency Syndromes, vol. 50, no. 3, pp. 299–306, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. A. S. Terzian, S. Holman, N. Nathwani et al., “Factors associated with preclinical disability and frailty among HIV-infected and HIV-uninfected women in the era of cART.,” Journal of women's health (2002), vol. 18, no. 12, pp. 1965–1974, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. K. W. Kooij, F. W. N. M. Wit, J. Schouten et al., “HIV infection is independently associated with frailty in middle-aged HIV type 1-infected individuals compared with similar but uninfected controls,” AIDS, vol. 30, no. 2, pp. 241–250, 2016. View at Publisher · View at Google Scholar · View at Scopus
  43. K. M. Erlandson, J. A. Schrack, C. M. Jankowski, T. T. Brown, and T. B. Campbell, “Functional impairment, disability, and frailty in adults aging with HIV-infection,” Current HIV/AIDS Reports, vol. 11, no. 3, pp. 279–290, 2014. View at Publisher · View at Google Scholar · View at Scopus
  44. K. K. Oursler, J. D. Sorkin, B. A. Smith, and L. I. Katzel, “Reduced aerobic capacity and physical functioning in older HIV-infected men,” AIDS Research and Human Retroviruses, vol. 22, no. 11, pp. 1113–1121, 2006. View at Publisher · View at Google Scholar
  45. K. Erlandson, A. Allshouse, C. Jankowski et al., “Comparison of functional status instruments in HIV-infected adults on effective antiretroviral therapy,” HIV Clinical Trials, vol. 13, no. 6, pp. 324–334, 2012. View at Publisher · View at Google Scholar · View at Scopus
  46. M. Greene, K. Covinsky, J. Astemborski et al., “The relationship of physical performance with HIV disease and mortality,” AIDS, vol. 28, no. 18, pp. 2711–2719, 2014. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Greene, K. E. Covinsky, V. Valcour et al., “Geriatric syndromes in older HIV-infected adults,” Journal of Acquired Immune Deficiency Syndromes, vol. 69, no. 2, pp. 161–167, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Longenberger, J. Y. Lim, T. T. Brown et al., “Low physical function as a risk factor for incident diabetes mellitus and insulin resistance,” Future Virology, vol. 6, no. 4, pp. 439–449, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. K. M. Erlandson, A. A. Allshouse, C. M. Jankowski et al., “Risk factors for falls in HIV-infected persons,” Journal of Acquired Immune Deficiency Syndromes, vol. 61, no. 4, pp. 484–489, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. K. M. Erlandson, A. A. Allshouse, C. M. Jankowski, S. Mawhinney, W. M. Kohrt, and T. B. Campbell, “Relationship of physical function and quality of life among persons aging with HIV infection,” AIDS, vol. 28, no. 13, pp. 1939–1943, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. K. M. Akgün, J. P. Tate, K. Crothers et al., “An Adapted Frailty-Related Phenotype and the VACS Index as Predictors of Hospitalization and Mortality in HIV-Infected and Uninfected Individuals,” Journal of Acquired Immune Deficiency Syndromes, vol. 67, no. 4, pp. 397–404, 2014. View at Publisher · View at Google Scholar
  52. D. A. Piggott, A. D. Muzaale, S. H. Mehta et al., “Frailty, HIV Infection, and Mortality in an Aging Cohort of Injection Drug Users,” PLoS ONE, vol. 8, no. 1, Article ID e54910, 2013. View at Publisher · View at Google Scholar · View at Scopus
  53. T. M. Gill, E. A. Gahbauer, H. G. Allore, and L. Han, “Transitions between frailty states among community-living older persons,” JAMA Internal Medicine, vol. 166, no. 4, pp. 418–423, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Cesari, B. Vellas, F.-C. Hsu et al., “A physical activity intervention to treat the frailty syndrome in older persons - Results from the LIFE-P study,” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, vol. 70, no. 2, pp. 216–222, 2015. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Pahor, J. M. Guralnik, W. T. Ambrosius et al., “Effect of structured physical activity on prevention of major mobility disability in older adults: the LIFE study randomized clinical trial,” The Journal of the American Medical Association, vol. 311, no. 23, pp. 2387–2396, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. E. Kelaiditi, G. A. Van Kan, and M. Cesari, “Frailty: Role of nutrition and exercise,” Current Opinion in Clinical Nutrition & Metabolic Care, vol. 17, no. 1, pp. 32–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  57. A. S. Bierman, “Functional status: The sixth vital sign,” Journal of General Internal Medicine, vol. 16, no. 11, pp. 785-786, 2001. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Marzolini, D. Back, R. Weber, and et al., “Swiss HIV Cohort Study Members. Ageing with HIV: medication use and risk for potential drug-drug interactions,” Journal of Antimicrobial Chemotherapy, vol. 66, pp. 2107–2111, 2011. View at Google Scholar
  59. B. Hasse, B. Ledergerber, H. Furrer et al., “Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study,” Clinical Infectious Diseases, vol. 53, no. 11, pp. 1130–1139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. E. J. Edelman, K. S. Gordon, J. Glover, I. R. McNicholl, D. A. Fiellin, and A. C. Justice, “The next therapeutic challenge in HIV: polypharmacy,” Drugs & Aging, vol. 30, no. 8, pp. 613–628, 2013. View at Publisher · View at Google Scholar
  61. B. M. Shah and E. R. Hajjar, “Polypharmacy, Adverse Drug Reactions, and Geriatric Syndromes,” Clinics in Geriatric Medicine, vol. 28, no. 2, pp. 173–186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. J. H. Gurwitz, T. S. Field, L. R. Harrold et al., “Incidence and preventability of adverse drug events among older persons in the ambulatory setting,” The Journal of the American Medical Association, vol. 289, no. 9, pp. 1107–1116, 2003. View at Publisher · View at Google Scholar · View at Scopus
  63. M. F. Wellons, L. Sanders, L. J. Edwards, J. A. Bartlett, A. E. Heald, and K. E. Schmader, “HIV infection: Treatment outcomes in older and younger adults,” Journal of the American Geriatrics Society, vol. 50, no. 4, pp. 603–607, 2002. View at Publisher · View at Google Scholar · View at Scopus
  64. D. M. Fick and T. P. Semla, “2012 American Geriatrics Society beers criteria: New year, new criteria, new perspective,” Journal of the American Geriatrics Society, vol. 60, no. 4, pp. 614-615, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Gallagher, C. Ryan, S. Byrne, J. Kennedy, and D. O'Mahony, “STOPP (Screening Tool of Older Person's Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation,” International Journal of Clinical Pharmacology and Therapeutics, vol. 46, no. 2, pp. 72–83, 2008. View at Publisher · View at Google Scholar · View at Scopus
  66. R. Scherzer, M. Gandhi, M. M. Estrella et al., “A chronic kidney disease risk score to determine tenofovir safety in a prospective cohort of HIV-positive male veterans,” AIDS, vol. 28, no. 9, pp. 1289–1295, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. G. A. McComsey, D. Kitch, E. S. Daar et al., “Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202,” The Journal of Infectious Diseases, vol. 203, no. 12, pp. 1791–1801, 2011. View at Publisher · View at Google Scholar · View at Scopus
  68. A. C. Achhra, M. Nugent, A. Mocroft, L. Ryom, and C. M. Wyatt, “Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments,” Current HIV/AIDS Reports, vol. 13, no. 3, pp. 149–157, 2016. View at Publisher · View at Google Scholar · View at Scopus
  69. S. W. Worm, C. Sabin, R. Weber et al., “Risk of myocardial infarction in patients with HIV infection exposed to spec ific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study,” The Journal of Infectious Diseases, vol. 201, no. 3, pp. 318–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Ryom, “Association between cardiovascular disease and contemporarily used protease inhibitors,” in Proceedings of the Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, Washington, USA, 2017.
  71. C. A. Sabin, S. W. Worm, R. Weber et al., “Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration,” The Lancet, vol. 371, no. 9622, pp. 1417–1426, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. J. Young, Y. Xiao, E. E. M. Moodie et al., “Effect of cumulating exposure to abacavir on the risk of cardiovascular disease events in patients from the swiss HIV cohort study,” Journal of Acquired Immune Deficiency Syndromes, vol. 69, no. 4, pp. 413–421, 2015. View at Publisher · View at Google Scholar · View at Scopus
  73. C. H. Brothers, J. E. Hernandez, A. G. Cutrell et al., “Risk of myocardial infarction and abacavir therapy: No increased risk across 52 glaxosmithkline-sponsored clinical trials in adult subjects,” Journal of Acquired Immune Deficiency Syndromes, vol. 51, no. 1, pp. 20–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. X. Ding, E. Andraca-Carrera, C. Cooper et al., “No association of abacavir use with myocardial infarction: findings of an FDA meta-analysis,” Journal of Acquired Immune Deficiency Syndromes, vol. 61, no. 4, pp. 441–447, 2012. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Cruciani, V. Zanichelli, G. Serpelloni et al., “Abacavir use and cardiovascular disease events: A meta-analysis of published and unpublished data,” AIDS, vol. 25, no. 16, pp. 1993–2004, 2011. View at Publisher · View at Google Scholar · View at Scopus
  76. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents., Version February 2017. Available at: http://aidsinfo.nih.gov/guidelines.
  77. F. Raffi, A. G. Babiker, L. Richert et al., “Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial,” The Lancet, vol. 384, no. 9958, pp. 1942–1951, 2014. View at Publisher · View at Google Scholar · View at Scopus
  78. J. A. Perez-Molina, R. Rubio, A. Rivero, and et al., “Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial,” The Lancet Infectious Diseases, vol. 15, pp. 775–784, 2015. View at Google Scholar
  79. P. Monteiro, I. Perez, M. Laguno et al., “Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: A pilot study,” Journal of Antimicrobial Chemotherapy, vol. 69, no. 3, Article ID dkt406, pp. 742–748, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. C. Gubavu, T. Prazuck, M. Niang et al., “Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients,” Journal of Antimicrobial Chemotherapy, vol. 71, no. 4, Article ID dkv430, pp. 1046–1050, 2016. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Guaraldi, Selecting First-line Antiretroviral Therapy in Older Patients: New Data, New Options, Key Considerations. Available at: http://www.clinicaloptions.com/HIV/Treatment%20Updates/ART%20in%20Older%20Patients/Clinical%20Thoughts/CT2.aspx.
  82. J. L. Blanco, G. Whitlock, A. Milinkovic, and G. Moyle, “HIV integrase inhibitors: A new era in the treatment of HIV,” Expert Opinion on Pharmacotherapy, vol. 16, no. 9, pp. 1313–1324, 2015. View at Publisher · View at Google Scholar · View at Scopus
  83. B. Gazzard, PM. Girard, and G. Di Perri, “Long-term efficacy and safety of E/C/F/TDF vs EFV/FTC/TDF and ATV+RTV+FTC/TDF in HIV-1-infected treatment-naive subjects ≥50 years,” Journal of the International AIDS Society, vol. 17, 2014. View at Google Scholar
  84. An observational retrospective database analysis to evaluate raltegravir based-regimens in aged HIV patients (RalAge)., https://clinicaltrials.gov/ct2/show/NCT02765776?term=elderly%2C+hiv&rank=1.
  85. Switching from a tenofovir disoproxil fumarate (TDF) containing regimen to elvitegravir/cobicistat/emtricitabine/ tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) in virologically-suppressed, HIV-1 infected adults aged ≥ 60 years. https://clinicaltrials.gov/ct2/show/NCT02616783?term=elderly%2C+hiv&rank=7.
  86. J. C. Schoen, K. M. Erlandson, and P. L. Anderson, “Clinical pharmacokinetics of antiretroviral drugs in older persons,” Expert Opinion on Drug Metabolism & Toxicology, vol. 9, no. 5, pp. 573–588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Pilotto, A. Cella, A. Pilotto et al., “Three decades of comprehensive geriatric assessment: evidence coming from different healthcare settings and specific clinical conditions,” Journal of the American Medical Directors Association, vol. 18, no. 2, pp. 192.e1–192.e11, 2017. View at Publisher · View at Google Scholar
  88. F. Panza, V. Solfrizzi, M. Lozupone et al., “An Old Challenge with New Promises: A Systematic Review on Comprehensive Geriatric Assessment in Long-Term Care Facilities,” Rejuvenation Research, 2017. View at Publisher · View at Google Scholar
  89. M. Greene, A. C. Justice, and K. E. Covinsky, “Assessment of geriatric syndromes and physical function in people living with HIV,” Virulence, pp. 1–13, 2016. View at Publisher · View at Google Scholar · View at Scopus
  90. M. D. John, M. Greene, N. A. Hessol et al., “Geriatric assessments and association with VACS index among HIV-infected older adults in San Francisco,” Journal of Acquired Immune Deficiency Syndromes, vol. 72, no. 5, pp. 534–541, 2016. View at Publisher · View at Google Scholar · View at Scopus